Red blood cell transfusion practices in extracorporeal membrane oxygenation: A single‐center study
Transfusion Medicine · 2025
DOI: 10.1111/tme.13154 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Transfusion Medicine, 2025. Verfasst von Shailesh Balasubramanian und 8 weiteren Autor:innen. Beteiligte Einrichtung: The Division of Pulmonary and Critical Care Medicine, Clinical Immunology, and Allergy, David Geffen School of Medicine at UCLA, Los Angeles, Califor…. Hauptthemen laut MEDLINE: Extracorporeal Membrane Oxygenation, Erythrocyte Transfusion, Hemoglobins. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
Evaluating blood transfusion practices and their impact on morbidity and mortality across extracorporeal membrane oxygenation (ECMO) configurations.
Background
As ECMO becomes increasingly utilised in critical care, the ideal Hgb level remains uncertain. While guidelines recommend higher levels, emerging evidence suggests potential harm. Our study addresses this gap by investigating the optimal Hgb level for ECMO.
Methods
A retrospective cohort study included all adult patients receiving ECMO between January 2016 and December 2018. The primary outcome assessed the optimal Hgb level associated with reduced ECMO duration and in‐hospital mortality. Multivariable and Cox‐proportional regression analyses were performed.
Results
A total of 306 patients underwent ECMO, with 31 patients having mean Hgb levels 7–7.9 g/dL, 176 patients 8–8.9 g/dL, 72 patients 9–9.9 g/dL, and 27 patients ≥10 g/dL. The mean (SD) age was 56 years (15), with 60.8% male (186/306). ECMO configurations were primarily Venoarterial (VA) (59.8%), followed by Venovenous (VV) (36.9%) and Hybrid (3.3%). The 7–7.9 g/dL Hgb group was associated with longer ECMO duration (mean 17.5 days, coefficient 2.2, 95% CI 0.02–4.4, p = 0.048) compared to the ≥10 g/dL group, with no significant mortality differences across Hgb levels. VA ECMO patients had a significantly higher mortality risk than VV ECMO patients (aHR 2.33, 95% CI 1.50–3.60, p < 0.001). Blood product use, including RBC and Cryo, was associated with longer ECMO duration, while FFP reduced both duration (coefficient − 0.84, 95% CI ‐1.11–‐0.57, p < 0.001) and mortality risk (aHR 0.895, 95% CI 0.818–0.973, p = 0.012).
Conclusion
Targeting Hgb level >8 g/dL in ECMO patients may help reduce ECMO duration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Division of Pulmonary and Critical Care Medicine, Clinical Immunology, and Allergy, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
- Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA.
- Department of Pulmonary and Critical Care Medicine, Respiratory Institute, Cleveland Clinic, Cleveland, Ohio, USA.
- Department of Intensive Care and Resuscitation, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
- Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic Hospital, Cleveland, Ohio, USA.
ORCID-Profile: Chase Donaldson, Brett Wakefield
Zitieren
APA
Balasubramanian, S., Alwakeel, M., Sadana, D., Latifi, M., Donaldson, C., Wakefield, B., Soltesz, E., McCurry, K., & Krishnan, S. (2025). Red blood cell transfusion practices in extracorporeal membrane oxygenation: A single‐center study. Transfusion Medicine. https://doi.org/10.1111/tme.13154
Vancouver
Balasubramanian S, Alwakeel M, Sadana D, Latifi M, Donaldson C, Wakefield B, et al. Red blood cell transfusion practices in extracorporeal membrane oxygenation: A single‐center study. Transfusion Medicine. 2025. doi:10.1111/tme.13154
BibTeX
@article{Balasubramanian2025,
author = {Balasubramanian, Shailesh and Alwakeel, Mahmoud and Sadana, Divyajot and Latifi, Mani and Donaldson, Chase and Wakefield, Brett and Soltesz, Edward and McCurry, Kenneth and Krishnan, Sudhir},
title = {Red blood cell transfusion practices in extracorporeal membrane oxygenation: A single‐center study},
journal = {Transfusion Medicine},
year = {2025},
doi = {10.1111/tme.13154}
}
EUVIMED